Related Experiment Video
Updated: Aug 16, 2026

10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress
Hong Ren1,2,3, Yukun Wu1,2,3, Yang Yang4
1Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China.
Bioactive Materials
|August 15, 2026
Summary
A novel hydrogel combats glaucoma by targeting oxidative stress and necroptosis, key drivers of retinal ganglion cell loss. This dual-action approach protects vision by interrupting a damaging cellular cycle.
Area of Science:
- Ophthalmology
- Neuroscience
- Biomaterials Science
Background:
- Glaucoma causes irreversible blindness through retinal ganglion cell (RGC) death.
- IOP-independent pathways, including oxidative stress and necroptosis, drive RGC loss.
- The RIPK1/RIPK3/MLKL pathway executes RGC death, amplified by oxidative stress.
Purpose of the Study:
- To develop a dual-targeted intervention strategy against the oxidative stress-necroptosis axis in glaucoma.
- To create a hierarchically responsive hydrogel (PD@Gel) for intravitreal delivery.
Main Methods:
- Dispersing Plantainoside D (PD)-loaded nanoparticles (PD@NPs) in thiolated hyaluronic acid (HA-SH) to form PD@Gel.
- Utilizing dynamic disulfide cross-linking for in situ gelation after intravitreal injection.
- Employing HA-SH as an extracellular ROS scavenger and PD@NPs for intracellular ROS capture and PD release.
Main Results:
- In vitro studies showed PD@Gel preserved mitochondrial potential and reduced necroptotic signaling.
- In vivo, a single intravitreal injection improved RGC survival in a murine retinal ischemia-reperfusion (I/R) model.
- The treatment downregulated necroptosis markers (p-RIPK1/p-MLKL) and partially restored visual function.
Conclusions:
- The PD@Gel system effectively interferes with the self-amplifying oxidative stress-necroptosis axis.
- This macro-to-micro platform demonstrates potential as a neuroprotective strategy for glaucoma.
- Targeting both oxidative stress and necroptosis offers a promising therapeutic avenue for RGC protection.

